SEC and FTC open two more in­ves­ti­ga­tions in­to Bio­gen's con­tro­ver­sial Alzheimer's drug ap­proval and mar­ket­ing prac­tices

Fol­low­ing Bio­gen’s an­nounce­ment of minis­cule 2021 sales for its con­tro­ver­sial new Alzheimer’s drug yes­ter­day, the com­pa­ny al­so re­vealed that the Fed­er­al Trade Com­mis­sion and the Se­cu­ri­ties and Ex­change Com­mis­sion have opened two new, sep­a­rate in­ves­ti­ga­tions in­to the trou­bled biotech.

The FTC, an an­titrust reg­u­la­tor, has re­quest­ed doc­u­ments re­lat­ed to a civ­il in­ves­tiga­tive de­mand, sim­i­lar to a sub­poe­na, on the mar­ket­ing and ap­proval of the Alzheimer’s drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER